Literature DB >> 15975372

Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction.

Yao Liang Tang1, Qiang Zhao, Xinyu Qin, Leping Shen, Leilei Cheng, Junbo Ge, M Ian Phillips.   

Abstract

BACKGROUND: There are several reports that engrafted mesenchymal stem cells (MSCs) stimulate angiogenesis in the ischemic heart, but the mechanism remains controversial. We hypothesize that transplantation of MSCs enhances vascular regeneration through a paracrine action.
METHODS: A transmural myocardial infarction was created by ligation of the left anterior descending coronary artery in rats. Those with an ejection fraction less than 0.70 1 week after myocardial infarction were included. Autologous MSCs (1 x 10(7); 0.2 mL) or culture medium (0.2 mL) was injected intramyocardially into the periinfarct zone (50 microL/injection at four sites; n = 20/group). At 2 weeks after transplantation, Western blot analysis was used to assay the paracrine factors and proapoptotic proteins. Echocardiography to assess heart function was performed on additional groups at 8 weeks after implantation.
RESULTS: The angiogenic factors basic fibroblast growth factor, vascular endothelial growth factor, and stem cell homing factor (stromal cell-derived factor -1alpha) increased in the MSC-treated hearts compared with medium-treated hearts. This was accompanied by a downregulation of proapoptotic protein Bax in ischemic myocardium. Similarly, capillary density increased about 40% in MSC-treated hearts compared with medium-treated hearts (p = 0.001). Left ventricular contractility, indicated by fractional shortening, improved in MSC-treated hearts at 2 months after implantation (MSCs: 48.6% +/- 19.9%; medium: 18.7% +/- 6.4%; p = 0.004).
CONCLUSIONS: Autologous MSC transplantation attenuates left ventricular remodeling and improves cardiac performance. The major mechanism appears to be paracrine action of the engrafted cells, increasing angiogenesis and cytoprotection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15975372     DOI: 10.1016/j.athoracsur.2005.02.072

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  139 in total

Review 1.  Cardiac cell therapy: boosting mesenchymal stem cells effects.

Authors:  E Samper; A Diez-Juan; J A Montero; P Sepúlveda
Journal:  Stem Cell Rev Rep       Date:  2013-06       Impact factor: 5.739

2.  Use of human embryonic stem cell derived-mesenchymal cells for cardiac repair.

Authors:  David L Simpson; Nolan L Boyd; Sunjay Kaushal; Steve L Stice; Samuel C Dudley
Journal:  Biotechnol Bioeng       Date:  2011-09-02       Impact factor: 4.530

3.  Photopolymerizable Hydrogel-Encapsulated Fibromodulin-Reprogrammed Cells for Muscle Regeneration.

Authors:  Pu Yang; Chenshuang Li; Min Lee; Anna Marzvanyan; Zhihe Zhao; Kang Ting; Chia Soo; Zhong Zheng
Journal:  Tissue Eng Part A       Date:  2020-06-02       Impact factor: 3.845

4.  Transplantation of Cardiac Mesenchymal Stem Cell-Derived Exosomes for Angiogenesis.

Authors:  Chengwei Ju; Youngjun Li; Yan Shen; Yutao Liu; Jingwen Cai; Naifeng Liu; Gengshan Ma; Yaoliang Tang
Journal:  J Cardiovasc Transl Res       Date:  2018-10-01       Impact factor: 4.132

5.  Suxiao Jiuxin pill promotes exosome secretion from mouse cardiac mesenchymal stem cells in vitro.

Authors:  Xiao-Fen Ruan; Cheng-Wei Ju; Yan Shen; Yu-Tao Liu; Il-Man Kim; Hong Yu; Neal Weintraub; Xiao-Long Wang; Yaoliang Tang
Journal:  Acta Pharmacol Sin       Date:  2018-03-15       Impact factor: 6.150

6.  Exosomes from Suxiao Jiuxin pill-treated cardiac mesenchymal stem cells decrease H3K27 demethylase UTX expression in mouse cardiomyocytes in vitro.

Authors:  Xiao-Fen Ruan; Yong-Jun Li; Cheng-Wei Ju; Yan Shen; Wei Lei; Can Chen; Yang Li; Hong Yu; Yu-Tao Liu; Il-Man Kim; Xiao-Long Wang; Neal L Weintraub; Yaoliang Tang
Journal:  Acta Pharmacol Sin       Date:  2018-03-15       Impact factor: 6.150

7.  Comparison of transplantation of adipose tissue- and bone marrow-derived mesenchymal stem cells in the infarcted heart.

Authors:  Koen E A van der Bogt; Sonja Schrepfer; Jin Yu; Ahmad Y Sheikh; Grant Hoyt; Johannes A Govaert; Jeffrey B Velotta; Christopher H Contag; Robert C Robbins; Joseph C Wu
Journal:  Transplantation       Date:  2009-03-15       Impact factor: 4.939

8.  Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells.

Authors:  Tom K Kuo; Shun-Pei Hung; Chiao-Hui Chuang; Chien-Tsun Chen; Yu-Ru V Shih; Szu-Ching Y Fang; Vincent W Yang; Oscar K Lee
Journal:  Gastroenterology       Date:  2008-03-12       Impact factor: 22.682

9.  Cell therapy generates a favourable chemokine gradient for stem cell recruitment into the infarcted heart in rabbits.

Authors:  Bai-Chin Lee; Hsiu-Ching Hsu; Wen-Yih I Tseng; Ching-Yi Chen; Hung-Ju Lin; Yi-Lwun Ho; Ming-Jai Su; Ming-Fong Chen
Journal:  Eur J Heart Fail       Date:  2009-01-12       Impact factor: 15.534

Review 10.  Mesenchymal stem cells secretome: a new paradigm for central nervous system regeneration?

Authors:  Fábio G Teixeira; Miguel M Carvalho; Nuno Sousa; António J Salgado
Journal:  Cell Mol Life Sci       Date:  2013-03-01       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.